Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)

This study has been completed.
Information provided by (Responsible Party):
Kaken Pharmaceutical Identifier:
First received: November 16, 2009
Last updated: October 17, 2013
Last verified: October 2013